Lifecare AS – Mandatory notification of trade

Bergen, Norway 26 April 2024: Hannibal Invest AS, a company closely associated with Hans Hekland, member of the Board of Directors of LifeCare AS (the “Company”), has on 26 April 2024 sold 150,000 shares in the Company at an average price of NOK 3.05 per share.

Following this transaction, Hannibal Invest AS holds 50,000 shares in the Company. The transaction is conducted to fund subscription of shares in the rights issue announced by the Company on 25 April 2024. Please see further details about the transaction in the attached form. This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

About us
Lifecare AS is a clinical stage medical sensor company developing technology for sensing and monitoring of various body analytes. Lifecare’s main focus is to bring the next generation of Continuous Glucose Monitoring (“CGM”) systems to market. Lifecare enables osmotic pressure as sensing principle, combined with the ability to manipulate Nano-granular Tunnelling Resistive sensors (“NTR”) on the sensor body for read-out of pressure variations. Lifecare’s sensor technology is referred to as “Sencell” and is suitable for identifying and monitoring the occurrence of a wide range of analytes and molecules in the human body and in pets.

Contacts
For further information, please contact:

Joacim Holter, CEO, Lifecare AS, joacim.holter@lifecare.no, +47 40 05 90 40

Asle Wingsternes, Head of Communications & Public Affairs, asle.wingsternes@lifecare.no, +47 41 61 42 52

This information is information that Lifecare AS is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-04-26 16:21 CEST.

Attachments
Lifecare AS – Mandatory notification of trade
240426 Hanibal Invest KRT 1500

Lifecare AS – Mandatory notification of trade
240426 Hanibal Invest KRT 1500